Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.70 |
| ▸ | CNR2 | P34972 | 11/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235335 | 0.91 | CNR1 (0.68) | CNR1CNR2KCNH2 | |
| SCHEMBL5236249 | 0.90 | CNR1 (0.75) | CNR1CNR2KCNH2 | |
| SCHEMBL5240619 | 0.88 | CNR1 (0.63) | CNR1CNR2KCNH2 | |
| SCHEMBL5379189 | 0.83 | CNR1 (0.50) | CNR1CNR2KCNH2 | |
| Otenabant SCHEMBL1622757 | 0.83 | CNR1 (1.00) | CNR1CNR2KCNH2 | |
| SCHEMBL5239445 | 0.83 | CNR1 (0.80) | CNR1CNR2KCNH2 | |
| SCHEMBL5233525 | 0.82 | CNR1 (0.72) | CNR1CNR2KCNH2 | |
| Otenabant SCHEMBL3932007 | 0.82 | CNR1 (0.98) | CNR1CNR2KCNH2 | |
| SCHEMBL5235768 | 0.81 | CNR1 (0.88) | CNR1CNR2 | |
| SCHEMBL5237430 | 0.81 | CNR1 (0.61) | CNR1CNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558615-B8 | PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2007-10-10 | — | — | EP | claimed |
| EP-1558615-B1 | PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2007-08-29 | — | — | EP | claimed |
| US-7129239-B2 | Purine compounds and uses thereof | PFIZER INC. (US) | 2006-10-31 | — | — | US | claimed |
| EP-1558615-A1 | PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| US-20040092520-A1 | Purine compounds and uses thereof | PFIZER INC. | 2004-05-13 | — | — | US | claimed |
| WO-2004037823-A1 | PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-05-06 | — | — | WO | claimed |
| EP-1558615-B8 | PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1558615-B1 | PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2007-08-29 | — | — | EP | disclosed |
| US-7129239-B2 | Purine compounds and uses thereof | PFIZER INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060241120-A1 | Cannabinoid Receptor Ligands and Uses Thereof | PFIZER INC | 2006-10-26 | — | — | US | disclosed |
| EP-1658082-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1626738-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1624895-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050043327-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2004098580-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004098641-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224963-A1 | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER INC | 2004-11-11 | — | — | US | disclosed |
| US-20040224962-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2004-11-11 | — | — | US | disclosed |
| US-20040092520-A1 | Purine compounds and uses thereof | PFIZER INC. | 2004-05-13 | — | — | US | disclosed |
| WO-2004037823-A1 | PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241120-A1 | Cannabinoid Receptor Ligands and Uses Thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885KCNH2 2953/4885 |
| US-20040092520-A1 | Purine compounds and uses thereof | CNR1, CNR2, P2RY1 | CNR1 1/4885CNR2 2/4885KCNH2 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.